knowledge -WSS

knowledge

author：explore 2025-09-29 21:25:27 - browse：1

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Commercial surrogacy can be ethical, despite pope’s claims

WSS

SAMSHA loosens regulations on methadone treatment centers

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Juul spent big to court Black leaders to promote its e

New safety details link Apellis eye drug to rare cases of blindness

Breakthrough Alzheimer’s drugs are inaccessible in rural states

Sage hopes for a blockbuster in antidepressant now before FDA

explore

knowledge

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Woodcock on FDA’s accelerated approval and her next chapter

Trump demands the U.S. pay no more for drugs than other countries … again

A $475,000 price tag for a new cancer drug: crazy or meh?

23andMe had bad news about my health. I wish a person had delivered it

New safety details link Apellis eye drug to rare cases of blindness

In Memoriam: Notable people who died in 2023

Even great ERs can’t make up for American health disparities

Continuity nursing helped my family in our darkest PICU moments

Micronoma's microbiome cancer diagnostic approach under fire

hotspot

SAMSHA loosens regulations on methadone treatment centers

Vertex non

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Physician groups backed by private equity giant lobby on mergers

Vertex non

Breakthrough Alzheimer’s drugs are inaccessible in rural states

hotspot

focus

entertainment

Wikipedia